Nothing Special   »   [go: up one dir, main page]

MX2009004164A - Metodo para aumentar la regeneracion de tejido. - Google Patents

Metodo para aumentar la regeneracion de tejido.

Info

Publication number
MX2009004164A
MX2009004164A MX2009004164A MX2009004164A MX2009004164A MX 2009004164 A MX2009004164 A MX 2009004164A MX 2009004164 A MX2009004164 A MX 2009004164A MX 2009004164 A MX2009004164 A MX 2009004164A MX 2009004164 A MX2009004164 A MX 2009004164A
Authority
MX
Mexico
Prior art keywords
tissue growth
tissue regeneration
enhance tissue
modulating
signaling pathways
Prior art date
Application number
MX2009004164A
Other languages
English (en)
Inventor
Leonard I Zon
Trista E North
Wolfram Goessling
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of MX2009004164A publication Critical patent/MX2009004164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona composiciones y métodos para modular el crecimiento de tejido utilizando moduladores de crecimiento de tejido, los cuales son agentes que ya sea que aumentan o inhiben el crecimiento de tejido como sea deseado por una indicación particular al modular las rutas de señalización de PG o de Wnt, o al emplear moduladores de ambas rutas de señalización de PG y de Wnt para un efecto sinergístico o efecto altamente selectivo.
MX2009004164A 2006-10-20 2007-10-22 Metodo para aumentar la regeneracion de tejido. MX2009004164A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85335106P 2006-10-20 2006-10-20
US85320206P 2006-10-20 2006-10-20
PCT/US2007/082093 WO2008070310A2 (en) 2006-10-20 2007-10-22 Method to enhance tissue regeneration

Publications (1)

Publication Number Publication Date
MX2009004164A true MX2009004164A (es) 2009-10-13

Family

ID=39492923

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004164A MX2009004164A (es) 2006-10-20 2007-10-22 Metodo para aumentar la regeneracion de tejido.

Country Status (9)

Country Link
US (3) US9402852B2 (es)
EP (3) EP3824885A1 (es)
JP (4) JP5426389B2 (es)
AU (1) AU2007329725B2 (es)
CA (1) CA2666972C (es)
HK (1) HK1133394A1 (es)
MX (1) MX2009004164A (es)
RU (1) RU2480213C2 (es)
WO (1) WO2008070310A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
EP2362733B1 (en) 2008-11-06 2017-04-12 Indiana University Research&Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
JP6037836B2 (ja) * 2009-11-15 2016-12-07 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法
US20120328631A1 (en) * 2010-03-05 2012-12-27 University Of Rochester Ep1 inhibition
AU2012206517B2 (en) * 2011-01-13 2016-12-01 Scipharm Sarl Method for Enhancing Engraftment of Haematopoietic Stem Cells
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
RU2559586C1 (ru) * 2014-06-10 2015-08-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ стимуляции регенерации резецированной печени дигидрокверцетином
RU2018106515A (ru) 2015-07-21 2019-08-21 Зе Чилдрен'С Медикал Сентер Корпорейшн Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
CN112334131B (zh) 2018-07-06 2024-04-05 Ck生物技术公司 包含靛玉红衍生物作为活性成分的药物组合物
AU2020267561A1 (en) * 2019-05-08 2021-12-23 Capricor, Inc. Therapeutically active cells and exosomes

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US704057A (en) 1901-10-21 1902-07-08 Sandford Northrop Expansible boring-tool.
ATE194651T1 (de) * 1989-10-16 2000-07-15 Amgen Inc Stammzellenfaktor
CA2168091A1 (en) 1993-08-23 1995-03-02 Stephen L. Smith In vitro growth of neutrophil and megakaryocyte precursors in serum-free media
AU6125396A (en) 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
CA2262469C (en) * 1996-08-16 2005-11-22 Genentech, Inc. Uses for wnt polypeptides
US6372796B1 (en) * 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
RU2259830C2 (ru) * 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
TWI247606B (en) * 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
WO2003055989A2 (en) * 2001-12-21 2003-07-10 Mount Sinai Hospital Cellular compositions and methods of making and using them
RU2205627C1 (ru) 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
ES2393321T3 (es) * 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2518193A1 (en) * 2003-03-04 2004-09-16 Pfizer Products Inc. Use of ep2 selective receptor agonists in medical treatment
EP1601759A4 (en) * 2003-03-07 2007-02-14 Gamida Cell Ltd EXPANSION OF RENEWABLE STEM CELL POPULATIONS USING PI-3 KINASE MODULATORS
EP1613742A2 (en) 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
WO2005028678A2 (en) * 2003-06-06 2005-03-31 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
AU2004249812B8 (en) * 2003-06-25 2011-09-15 Ottawa Hospital Research Institute Methods and compositions for modulating stem cell growth and differentiation
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
WO2005040351A2 (en) * 2003-10-24 2005-05-06 California Institute Of Technology Compositions for inducing cell growth and differentiation and methods of using same
US8309608B2 (en) * 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
MXPA06015170A (es) * 2004-06-21 2007-08-21 Pharmacia & Upjohn Co Llc Procedimiento para aumentar la cantidad de hueso.
WO2006005153A1 (en) 2004-07-09 2006-01-19 Bc Cancer Agency Nup98-hox fusions for expansion of hemopoietic stem cells
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
WO2006078886A2 (en) * 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
CA2597757C (en) 2005-02-10 2016-06-28 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
US20080194024A1 (en) 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
WO2007070964A1 (en) 2005-12-22 2007-06-28 Es Cell International Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
CA2647201C (en) 2006-03-24 2016-03-08 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
US8241903B2 (en) 2006-06-22 2012-08-14 Yeda Research And Development Co., Ltd. Catecholamine receptor modulation
WO2008021475A2 (en) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
KR20080042761A (ko) 2006-11-10 2008-05-15 문찬일 렙틴을 이용한 줄기세포 증식방법

Also Published As

Publication number Publication date
JP2010507592A (ja) 2010-03-11
EP2077826A4 (en) 2010-05-26
WO2008070310A3 (en) 2008-12-18
EP2077826A2 (en) 2009-07-15
EP2077826B1 (en) 2013-09-04
HK1133394A1 (en) 2010-03-26
CA2666972C (en) 2015-12-29
EP3824885A1 (en) 2021-05-26
AU2007329725A1 (en) 2008-06-12
WO2008070310A2 (en) 2008-06-12
JP2019189661A (ja) 2019-10-31
US9402852B2 (en) 2016-08-02
CA2666972A1 (en) 2008-06-12
RU2009118942A (ru) 2010-11-27
US20160354385A1 (en) 2016-12-08
AU2007329725B2 (en) 2013-05-23
JP2016121180A (ja) 2016-07-07
US10736906B2 (en) 2020-08-11
JP5426389B2 (ja) 2014-02-26
US20210077505A1 (en) 2021-03-18
RU2480213C2 (ru) 2013-04-27
EP2679221A1 (en) 2014-01-01
EP2679221B1 (en) 2020-09-23
US20110009370A1 (en) 2011-01-13
JP2014065723A (ja) 2014-04-17

Similar Documents

Publication Publication Date Title
MX2009004164A (es) Metodo para aumentar la regeneracion de tejido.
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
MX2019007494A (es) Metodo para modular el crecimiento de celulas madre hematopoyeticas.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MY148253A (en) Azaadamantane derivatives and methods of use
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2010025295A3 (en) Compounds that modulate intracellular calcium
AU2007257423A8 (en) Purine analogs
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
UA113397C2 (xx) Попередження несприятливих ефектів, спричинених специфічними доменами зв&#39;язування cd3
MX2010002712A (es) Compuestos que modulan calcio intracelular.
SG169988A1 (en) Rnai inhibition of alpha-enac expression
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
WO2010048559A3 (en) Phenylpyrazole inhibitors of store operated calcium release
WO2011034962A3 (en) Compounds that modulate intracellular calcium
WO2007120815A3 (en) Methods for treating lymphocyte-associated disorders by modulation of siglec activity
WO2008088820A3 (en) Glutamate receptor antagonists and methods of use
WO2008033499A3 (en) Modulation of regulatory t cells by human il-18

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CHILDREN S MEDICAL CENTER CORPORATION

FG Grant or registration